

Cyclooxygenase 2 (COX-2) inhibition neutralized ICAM-1 modulation in liver microenvironment during metastatic development

Herrero A, Benedicto A, Olaso E, Arteta B.
Department of Cell Biology and Histology, University of the Basque Country,
School of Medicine and Nursery

eman ta zabal zazu

Universidad del País Vasco Euskal Herriko Unibertsitatea

MEDIKUNTZA
ETA ERIZAINITZA
FAKULTATEA
FACULTAD
DE MEDICINA
Y ENFERMERÍA

INTRODUCTION

During metastatic progression, the liver microenvironment is modulated to promote tumor development. In liver sinusoids, colorectal cancer cells adhere to liver sinusoidal endothelial cells (LSECs), triggering a pro-metastatic cascade and creating a pro-inflammatory and pro-angiogenic microenvironment. Our group has previously shown that ICAM-1 accounts for the up-regulation of inflammatory molecules such as IL-1 β , IL-6, PGE₂ and TNF- α within the tumor microenvironment (TME) in early phases of liver colonization and that this process is modulated by the inhibition of COX-2, the limiting enzyme in the synthesis of PGE₂. Even though several studies support the role of COX-2 in metastatic progression to the liver, little is known about its role in the angiogenic and fibrogenic response modulated by ICAM-1.

AIM

Our study aims to analyze the intracellular mechanisms by which ICAM-1 promotes those responses and their modulation by COX-2, focusing on the role of LSECs and hepatic stellate cells (HSCs) crosstalk with metastatic cancer cells.

METHODS

First, we analyzed the effect of tumor activation by soluble ICAM-1 (sICAM-1) and by co-culture with LSECs in COX-2 activity and subsequent production of PGE₂ and VEGF, central mediators of the inflammatory and angiogenic responses within the TME.

Second, to confirm the involvement of COX-2 activity in the process, we proceeded to inactivate the enzyme by the specific inhibitor Celecoxib. Afterwards, the level of PGE₂ and VEGF was quantified by ELISA.

Finally, we analyzed the migration of primary mouse LSECs and HSCs, main actors of angiogenesis, and desmoplastic response during liver metastasis, upon activation with Celecoxib treated tumor secretomes after sICAM-1 stimulation.

RESULTS




Figure 1. ICAM-1 induced PGE₂ and VEGF production via COX-2 activation on C26 cells. Inhibition of COX-2 activity with CLX reduced PGE₂ and VEGF production after the activation of sICAM-1 in C26 cells. Results were considered significant when p<0'05 (* sICAM-1 treated vs untreated, and # for CLX treated vs CLX untreated) and p<0'01 (##), by *T Student.




Figure 2. Effect of COX-2 activity inhibition on PGE₂ and VEGF secretion in LSEC-C26 co-cultures. PGE₂ and VEGF production were stimulated by interaction between tumor cells C26 and LSECs. This effect was abrogated after COX-2 inhibition by celecoxib. Results were considered significant when p<0'05 (*, respect control (only LSEC culture) and # for CLX untreated respect CLX treated) and p<0'01 (##), by *T Student.

CONCLUSIONS

Tumor cell activation with sICAM-1 increased intracellular COX-2 activity resulting in an increased PGE₂ and VEGF secretion in the supernatants. The same effect was reported in co-cultures of tumor cells and LSECs. COX-2 inhibition by Celecoxib decreased COX-2 activation and the production of both PGE₂ and VEGF by tumor cells and co-cultures. Besides, secretomes of sICAM-1 stimulated tumor cells burst the migration of both LSECs and HSCs compared to that of untreated tumor cells through a reciprocal interaction. This sICAM-1 mediated effect was abrogated upon Celecoxib treatment of tumor cells, leading to decreased migration of LSECs and HSCs.





Figure 3. Reciprocal activation of the migratory activity on stromal cells by ICAM-1 stimulation of tumor cells is dependent on COX-2 activity. HSCs migratory capacity increased by tumors-activated LSECs secretome. Moreover, the sICAM-1 activation in C26 increased the migratory capacity of HSCs that was reduced by COX-2 inhibition. In LSECs, activated HSCs secretome increased the capacity migrations, especially after sICAM-1 activation of tumor cells. This capacity was reduced by COX-2 inhibition. Results were considered significant when p<0'05 (*, respect HSCs (A) and LSECs (B) and # for CLX untreated respect CLX treated) and p<0'01 (**), by *T Student.




Figure 4. In vivo recruitment of ASMA+ cells and collagen deposition in livers of C26-bearing mice. Liver collected from sICAM-1- activated C26 bearing mice showed increase ASMA+ cell recruitment and collagen deposition compared to those liver collected from control C26-bearing mice. This increase was abrogated by treatment with the COX-2 inhibitor celecoxib.

REFERENCES

Benedicto A, et al. Liver sinusoidal endothelial cell ICAM-1 mediated tumor/endothelial crosstalk drives the development of liver metastasis by initiating inflammatory and angiogenic responses. *Sci Rep.* 2019.
Arteta B, et al. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. *Hepatology.* 2010.

CONTACT INFORMATION

Herrero ,A: alba1808@gmail.com
Benedicto, A: aitor.benedicto@ehu.es
Arteta, B: beatriz.arteta@ehu.es